www.astro.org
Abstract # 2193 Quality of Life during Adjuvant Chemoradiation for Gastric Adenocarcinoma

Presenter: Ringash, Jolie

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos


Results:
Mean age was 56 years (31‐77), with M: F 55: 45%. Compliance was 74‐97% at all time points. Median follow up was 2.7 years (0.3‐5). Three‐year overall and relapse free survival were 83% and 71%, with median survival not reached. Median scores on global and functional scales, except cognitive and physical, showed clinically significant worsening at completion of radiation therapy, with statistically significant worsening in all but cognitive and emotional scales (median differences: global ‐29 p=<0.0001, physical ‐7 p=0.0002, role ‐33 p=<0.0001, emotion ‐13 p=0.06, cognitive 0 p=0.29, social ‐17 p=0.002). At 4 weeks post chemotherapy, only global QOL remained depressed compared to baseline (median difference ‐8 p=0.0002). By 6‐12 months post chemotherapy none of the subscales showed clinically or statistically significant differences from baseline scores on average, but between 10‐40% of patients had worsened scores on at least one subscale (range 1‐5). There was no association of global QOL and functional scores with the experience of DLT, and no association of functional scores with escalating dose cohorts. However, a significant linear association was found for global QOL, with escalating doses cohorts associated with worse scores (p=0.0007).